Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 8:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 214 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Amphetamine Sulfate Clear all
Not listed Not applicable Interventional

A Cognitive Behavioral Therapy-Based Text Message Intervention for Methamphetamine Dependence

NCT01899313
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
CBT- based SMS text messaging intervention, CBT group therapy
Behavioral
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
2
States / cities
Lafayette, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Sep 2, 2026, 8:03 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Enhancing Operational Performance in Healthy Rested Soldiers With Pharmacological Stimulants

NCT03893032
View directory record Official record
Conditions
Cognition
Interventions
Modafinil 200mg, mixed amphetamine salts, Placebo
Drug
Lead sponsor
United States Army Aeromedical Research Laboratory
Federal
Eligibility
18 Years to 40 Years · Male only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Fort Rucker, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Sep 2, 2026, 8:03 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Efficacy Study of Lisdexamfetamine to Treat Bipolar Depression

NCT01093963
View directory record Official record
Conditions
Bipolar Depression
Interventions
Lisdexamfetamine, Placebo
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 1, 2015 · Synced Sep 2, 2026, 8:03 PM EDT
Completed Phase 2 Interventional Results available

Dextroamphetamine and tDCS to Improve the Fluency

NCT02514044
View directory record Official record
Conditions
Stroke
Interventions
Dexedrine, Active tDCS, Speech Therapy, Placebo, Sham tDCS
Drug · Device · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Sep 2, 2026, 8:03 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder

NCT02466386
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SPD489
Drug
Lead sponsor
Shire
Industry
Eligibility
4 Years to 5 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
50
States / cities
Dothan, Alabama • Little Rock, Arkansas • Imperial, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Sep 2, 2026, 8:03 PM EDT
Completed No phase listed Observational

IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents

NCT01232361
View directory record Official record
Conditions
ADHD, HIV
Interventions
Not listed
Lead sponsor
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Network
Eligibility
6 Years to 25 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
21
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Sep 2, 2026, 8:03 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

NCT01552915
View directory record Official record
Conditions
Attention-deficit/Hyperactivity Disorder
Interventions
Lisdexamfetamine dimesylate, Methylphenidate Hydrochloride, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
13 Years to 17 Years
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
79
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • National City, California + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Sep 2, 2026, 8:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Attention Deficit Hyperactivity Disorder (ADHD) Smoking Cessation Study

NCT00736255
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Nicotine Dependence
Interventions
Transdermal Nicotine Patch, Lis-dexamphetamine (Vyvanse), Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Sep 2, 2026, 8:03 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Safety & Efficacy of d-Amphetamine Transdermal System vs Placebo in Children & Adolescents With ADHD

NCT01711021
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
d-Amphetamine Transdermal Patch, Placebo patch
Drug
Lead sponsor
Noven Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Irvine, California • Miami, Florida • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Sep 2, 2026, 8:03 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

NCT01436149
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SPD489 (Lisdexamfetamine dimesylate ), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
47
States / cities
Birmingham, Alabama • Carson, California • Irvine, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 2, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug Interaction Study of SPD503 and Vyvanse Administered Alone and In Combination in Normal Healthy Volunteers

NCT00919867
View directory record Official record
Conditions
Healthy
Interventions
SPD503, VYVANSE, SPD503 and VYVANSE
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 2, 2026, 8:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories

NCT00247572
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders, Substance-Related Disorders
Interventions
NRP104
Drug
Lead sponsor
New River Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2007 · Synced Sep 2, 2026, 8:03 PM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder

NCT01074294
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
OPDC-34712, Placebo, Stimulant Therapy
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
35
States / cities
Little Rock, Arkansas • Beverly Hills, California • Irvine, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Sep 2, 2026, 8:03 PM EDT
Completed Phase 2 Interventional

A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADHD

NCT02884544
View directory record Official record
Conditions
Attention-Deficit Hyperactivity Disorder (ADHD)
Interventions
HLD100
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
6 Years to 12 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 18, 2021 · Synced Sep 2, 2026, 8:03 PM EDT
Completed Not applicable Interventional Results available

Should Chronic Stimulant Medications be Continued Preoperatively in Patients With Attention Deficit Hyperactivity Disorder(ADHD)

NCT01740206
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Amphetamine and/or methylphenidate, Hold stimulant medication
Drug · Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
2 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Sep 2, 2026, 8:03 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Cocaine Dependence With Lisdexamfetamine

NCT00958282
View directory record Official record
Conditions
Cocaine Dependence
Interventions
lisdexamfetamine/Behavior Therapy, placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 16, 2015 · Synced Sep 2, 2026, 8:03 PM EDT
Completed Phase 3 Interventional

Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

NCT00334880
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity, Attention Deficit Hyperactivity Disorders
Interventions
NRP104
Drug
Lead sponsor
New River Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
48
States / cities
Little Rock, Arkansas • El Centro, California • Irvine, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2009 · Synced Sep 2, 2026, 8:03 PM EDT
Completed Phase 4 Interventional Results available

Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Major Depressive Disorder.

NCT01148979
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Lisdexamfetamine Dimesylate (Vyvanse), Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Sep 2, 2026, 8:03 PM EDT
Completed Phase 2 Interventional Results available

Modafinil Versus Amphetamines for the Treatment of Narcolepsy Type 2 and Idiopathic Hypersomnia

NCT03772314
View directory record Official record
Conditions
Idiopathic Hypersomnia, Narcolepsy Without Cataplexy
Interventions
Modafinil, Amphetamine-Dextroamphetamine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Sep 2, 2026, 8:03 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Adjunctive Lisdexamfetamine (LDX) in Bipolar Depression

NCT01131559
View directory record Official record
Conditions
Bipolar, Depression
Interventions
Lisdexamfetamine, Placebo control
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Sep 2, 2026, 8:03 PM EDT
Terminated Phase 3 Interventional Results available

Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia

NCT01738698
View directory record Official record
Conditions
Schizophrenia
Interventions
SPD489 40mg, SPD489 100mg, SPD489 160mg, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Irving, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Sep 2, 2026, 8:03 PM EDT
Completed Phase 3 Interventional Results available

A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)

NCT00500149
View directory record Official record
Conditions
ADHD
Interventions
Vyvanse (lisdexamfetamine dimesylate), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 12 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
9
States / cities
Little Rock, Arkansas • Irvine, California • Wildomar, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 2, 2026, 8:03 PM EDT
Completed Phase 1 Interventional

Agonist Replacement Therapy for Cocaine Dependence

NCT00697138
View directory record Official record
Conditions
Cocaine Dependence
Interventions
d-Amphetamine; Atomoxetine
Drug
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years to 50 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 29, 2012 · Synced Sep 2, 2026, 8:03 PM EDT
Completed No phase listed Observational

Amphetamine Induced Adult Respiratory Distress Syndrome

NCT05611385
View directory record Official record
Conditions
Burns, Acute Lung Injury, Acute Respiratory Distress Syndrome, Methamphetamine Abuse
Interventions
Difference in development of Acute Lung Injury in Amphetamine positive and negative patients
Other
Lead sponsor
Arrowhead Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Colton, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Sep 2, 2026, 8:03 PM EDT